Oncology: International Journal of Cancer Research and Treatment
Fecha de publicación:
Autores: Matsuura N., Motoori M., Fujitani K., Nishizawa Y., Komatsu H., Miyazaki Y., Miyazaki S., Tomokuni A., Komori T., Iwase K.
Background: Neoadjuvant chemotherapy (NAC) followed by surgery is a promising treatment strategy for patients with advanced gastric cancer. Severe toxicity associated with the treatment may reduce the dose intensity of chemotherapy, resulting in the effect of chemotherapy being attenuated. Recently, skeletal muscle mass has been reported to be associated with the treatment outcomes of cancer patients. The purpose of this study was to clarify whether pretreatment skeletal muscle mass is a predictor of adverse events as well as the relationship between changes in skeletal muscle mass and adverse events during NAC.Leer más